Skip to content

Cannabis: all studies

Page 194 of 295: studies 1,931 to 1,940 of 2,943, newest first. Back to the cannabis overview

Research

Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.

Early Intervention in Psychiatry January 2024 Amar Ghelani

Cannabis is used by one third of youth in Early Psychosis Intervention (EPI) programs and high dose consumption of the primary constituent Δ-9 tetrahydrocannabinol (THC) is associated with higher risk for relapse in this group. Cannabidiol (CBD) is a secondary cannabis constituent that may have antipsychotic properties, though its health risks are only beginning to be understood. Little is...

A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids.

Frontiers in Psychiatry 2024 David J Heal, Jane Gosden, Sharon L. Smith

Various countries and US States have legalized cannabis, and the use of the psychoactive1 and non-psychoactive cannabinoids is steadily increasing. In this review, we have collated evidence from published non-clinical and clinical sources to evaluate the abuse, dependence and associated safety risks of the individual cannabinoids present in cannabis. As context, we also evaluated various...

Survey of U.S. Residents and Their Usage of Electronic Cigarettes with Drugs Other Than Nicotine.

Journal of Psychoactive Drugs 2024 Alaina K Holt, Alyssa K Rudy, Ashlee N Sawyer et al. 2 citations

Electronic cigarettes (e-cigs), originally intended to be used as cigarette substitutes, have evolved into discreet devices for consuming drugs other than nicotine (DOTNs). Presented are the results of an exploratory survey in which information regarding demographics, e-cig device type, DOTN use, frequency and context of use was collected. The average reported age of respondents was 27.4 years...

DOI: 10.1080/02791072.2023.2250353 (opens in new tab) Full text (opens in new tab) United states Substance use Vaping e-cigarettes Electronic cigarettes +5

Sleep Disorders and Dual Disorders

European Psychiatry November 17, 2023 L. Fernandez Mayo, D. Baño Rodrigo, E. Barbero García et al.

Introduction While it is well known that there is an interaction between sleep disorders and substance abuse, it is certainly more complex than was previously thought. The effects on sleep depend on the substance used, but it has been shown that both during use and in withdrawal periods consumers have various sleep problems, and basically more fragmented sleep. We know that sleep problems must...

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses.

Psychological Medicine November 2023 Matthew N Hill, Margaret Haney, Cecilia J. Hillard et al.

Cannabis is well established to impact affective states, emotion and perceptual processing, primarily through its interactions with the endocannabinoid system. While cannabis use is quite prevalent in many individuals afflicted with psychiatric illnesses, there is considerable controversy as to whether cannabis may worsen these conditions or provide some form of therapeutic benefit. The...

The Use of Illicit Drugs in Therapy: an Introduction

Current Addiction Reports September 8, 2023 Anna Ross, Jake Hawthorn

Abstract Purpose of Review The use of certain illicit substances as a form of therapy, and particularly as an adjunct to psychotherapy, has gained increasing media and academic attention over the last decade, culminating in what has been coined “the psychedelic renaissance.” This section in Current Addiction Reports has been developed in order to highlight the new and emerging research around...

Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia

Journal of Addictive Diseases August 4, 2023 Ruzmayuddin Mamat, Rusdi Abd Rashid, Baharudin Ibrahim et al. 2 citations

Psilocybin in vaping is growing among ATS users and across all populations. Unfortunately, knowledge regarding the long-term effects on health is limited. Further studies should highlight the harmful effects of psilocybin and the potential risk of psilocybin vaping among the younger population.

Cannabidiol tempers alcohol intake and neuroendocrine and behavioural correlates in alcohol binge drinking adolescent rats. Focus on calcitonin gene‐related peptide's brain levels

Phytotherapy Research July 31, 2023 Giuseppe Tringali, Gianluca Lavanco, Valentina Castelli et al. 17 citations

Alcohol binge drinking is common among adolescents and may challenge the signalling systems that process affective stimuli, including calcitonin gene-related peptide (CGRP) signalling. Here, we employed a rat model of adolescent binge drinking to evaluate reward-, social- and aversion-related behaviour, glucocorticoid output and CGRP levels in affect-related brain regions. As a potential...

DOI: 10.1002/ptr.7972 (opens in new tab) Cannabidiol Cannabis Binge drinking Calcitonin gene-related peptide +10

The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review.

Neuroscience & Biobehavioral Reviews July 1, 2023 Manoj K. Doss, Harriet de Wit, David A Gallo 30 citations

Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic memories, specifically encoding (forming memories), consolidation (stabilizing memories), and retrieval (accessing memories). Drugs administered before encoding may preferentially...

Social Psychopharmacology: Novel Approaches to Treat Deficits in Social Motivation in Schizophrenia

Schizophrenia Bulletin June 26, 2023 Anya K. Bershad, Harriet de Wit 12 citations

BACKGROUND AND HYPOTHESIS: Diminished social motivation is a negative symptom of schizophrenia and leads to severe functional consequences for many patients suffering from the illness. However, there are no effective medications available to treat this symptom. Despite the lack of approved treatments for patients, there is a growing body of literature on the effects of several classes of drugs...

DOI: 10.1093/schbul/sbad094 (opens in new tab) Full text (opens in new tab) MDMA Cannabis Schizophrenia object-oriented programming Psychosocial +7